【LBA6504：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts.】【LBA3：Resu
讲者：姜尔烈
单位：中国医学科学院血液病医院
【7507：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)】【7500：MRD-driven strategy following IsaKRD induction in transplant-e
讲者：贡铁军
单位：哈尔滨血液病肿瘤研究所
讲者：宋玉琴
单位：北京大学肿瘤医院
【8006：Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.】【LBA8008：Tarlatamab versus standard of
讲者：张良
单位：吉林省肿瘤医院/吉林省第二人民医院
LBA8001：Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
讲者：王琳琳
单位：山东省肿瘤医院
【8503：Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertionmutations who received prior platinum-based chemotherapy with orwithout amivantamab.】【8500：First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients(pts) with advanced/me
讲者：周斐
单位：上海市东方医院
讲者：王志杰
单位：中国医学科学院肿瘤医院
LBA500：De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
讲者：葛睿
单位：复旦大学附属华东医院
【501：Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial
讲者：李俊杰
单位：复旦大学附属肿瘤医院
讲者：王殊
单位：北京大学人民医院
